DG
ABCL icon

David Goel’s AbCellera Biologics ABCL Stock Holding History

David Goel’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-250,000
Closed -$10.1M – 31
2020
Q4 		$10.1M Buy
+250,000
New +$11.4M 0.11% 29

Other funds holding ABCL

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

David Goel's ABCL Position: Q1 2021 in Review

David Goel sold out of AbCellera Biologics (ABCL) in Q1 2021, closing a stake of 250,000 shares — an estimated $10.1M sold.

David Goel first reported a position in ABCL in Q4 2020 and held it in 1 quarter. The position peaked at $10.1M in Q4 2020. 86 funds tracked by Wall St. Rank hold ABCL as of Q1 2021.

  • David Goel reported no remaining AbCellera Biologics position as of Q1 2021 after selling out during the quarter.
  • David Goel sold 250,000 AbCellera Biologics shares in Q1 2021, an estimated $10.1M.
  • David Goel first reported a position in AbCellera Biologics in Q4 2020 and held it in 1 quarter.
  • David Goel's AbCellera Biologics position peaked at $10.1M in Q4 2020.
  • 86 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2021.

Based on Matrix Capital Management Company's 13F filing for Q1 2021, filed 17 May 2021.